GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (FRA:04I) » Definitions » Median PS Value

InVivo Therapeutics Holdings (FRA:04I) Median PS Value : €0.00 (As of Jun. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is InVivo Therapeutics Holdings Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. InVivo Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was €0. InVivo Therapeutics Holdings's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is €0.00.

As of today (2024-06-14), InVivo Therapeutics Holdings's share price is €0.2545. InVivo Therapeutics Holdings's Median PS Value is €0.00. Therefore, InVivo Therapeutics Holdings's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for InVivo Therapeutics Holdings's Median PS Value or its related term are showing as below:

FRA:04I's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.66
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

InVivo Therapeutics Holdings Median PS Value Historical Data

The historical data trend for InVivo Therapeutics Holdings's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InVivo Therapeutics Holdings Median PS Value Chart

InVivo Therapeutics Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

InVivo Therapeutics Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of InVivo Therapeutics Holdings's Median PS Value

For the Biotechnology subindustry, InVivo Therapeutics Holdings's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InVivo Therapeutics Holdings's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where InVivo Therapeutics Holdings's Price-to-Median-PS-Value falls into.



InVivo Therapeutics Holdings Median PS Value Calculation

InVivo Therapeutics Holdings's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0*
=0.00

10-Year Median PS Ratio is .
InVivo Therapeutics Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InVivo Therapeutics Holdings  (FRA:04I) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

InVivo Therapeutics Holdings's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.2545/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InVivo Therapeutics Holdings Median PS Value Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


InVivo Therapeutics Holdings (FRA:04I) Business Description

Traded in Other Exchanges
Address
One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139
InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.

InVivo Therapeutics Holdings (FRA:04I) Headlines

No Headlines